Final remarks and presentation of awards.
FDA Approves Revumenib for Relapsed/Refractory KMT2A-Translocated Acute Leukemia
The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Nilotinib Tablets Approved by FDA for Ph+ CML in Chronic Phase
Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
FDA Approves Obecabtagene Autoleucel in B-Cell ALL
Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.
Real-World Data Confirm Brexu-cel Use in Relapsed/Refractory B-ALL
Consolidative hematopoietic cell transplantation also confers improved progression-free survival among those with relapsed/refractory B-ALL.
